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A B S T R A C T
From a patient-centric perspective, oromucosal drug delivery is highly attractive due to the ease of adminis-
tration without the need of swallowing, and improved patient safety. The aim of the presented work was to
prepare a buccal film using a self-forming micellar drug solubiliser as the film matrix, combining it with a
mucoadhesive polymer for an enhanced retention on the buccal mucosa. Specifically, we propose the use of a
graft co-polymer (Soluplus®), as a solubiliser and film former, supplemented with polymers with more hydro-
philic properties and known mucoadhesive properties; hydroxypropyl methylcellulose (HPMC) or modified
hydroxypropyl pea starch (Lycoat®). The film was manufactured by the solvent casting method. The resulting
dual polymer film containing HPMC exhibited resistance to erosion and mucoadhesive properties superior to the
control films of single polymers. In an in vitro oral cavity model, these properties were shown to correlate with
increased residence time on simulated oral mucosa. Furthermore, all films containing the graft co-polymer
showed similar permeability characteristics of furosemide towards buccal TR146 epithelial cells. This work
illustrated that it is possible to manufacture dry, solid, dual polymer films containing an advanced drug delivery
system with a cheap and simple method. The combination of a graft co-polymer with a mucoadhesive polymer
transform into drug solubilising micelles in a mucin-retentive hydrogel scaffold with longer retention time on
buccal mucosa for safe and enhanced advanced formulation.
1. Introduction
The oral route is the most preferred drug administration route;
however, many patients find it difficult to swallow tablets and capsules.
Many drug formulations have been developed in order to overcome the
swallowing problem, including oral gels, buccal tablets, patches and
various kind of fast dissolving drug delivery systems, just to name a few.
Even with rapidly dissolving systems, a fear of choking may persist in
some patients. Mucoadhesive buccal films offer many advantages over
other oral formulations; the film is designed to attach to the buccal
mucosa and release the drug in a controlled manner, for either trans-
mucosal or local therapy. The buccal trans-mucosal administration of
drugs is a non-invasive route for systemic administration that has many
advantages over oral administration, such as a more rapid onset of
action due to rich vascularisation of the mucosa, bypassing the enzy-
matic degradation of the gastrointestinal tract, avoiding the first pass
metabolism and possibly improving bioavailability (Fonseca-Santos and
Chorilli, 2018; Hoffmann et al., 2011; Smart, 2005). Another advantage
is the easy access to the oral cavity and the buccal mucosa, which makes
application as well as removal of a drug delivery system simple for the
patient or the care giver (Pather et al., 2008). However, there are also
disadvantages associated with the natural functions of the oral cavity in
swallowing, speaking, eating and drinking. The oral mucosa is con-
stantly being rinsed by saliva, and the movements of the tongue and jaw
can further limit the usefulness of a buccally administered drug delivery
system (Laffleur, 2014). In addition, it is known that the drug perme-
ability of the buccal mucosa is lower as compared to the small intestine,
although low permeability may be compensated by longer residence
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time (Pather et al., 2008; Rathbone et al., 2015; Rathbone and
Hadgraft, 1991). Increased retention time on the buccal mucosa can be
achieved by selecting a mucoadhesive formulation.
Oral films can be either orodispersible, i.e. fast dissolving and in-
tended for swallowing, or mucoadhesive, intended for application on
the oral mucosa (Borges et al., 2015). Absorption of drug released from
the film occurs either trans-mucosal or in the GI tract, governed by the
properties of the film. The mucoadhesive buccal film is classified as a
prolonged release formulation, which can be single-layer or multi-layer
in action (Borges et al., 2015; Preis et al., 2013). Multi-layer films are
often designed as oral patches with a non-dissolvable layer promoting
uni-directional drug release, either for transmucosal absorption or for
local effect in the oral cavity where absorption is undesired
(Smart, 2005). Multi-layer films often need to be removed manually
(Preis et al., 2014c). Single-layer buccal films can be manufactured to
erode with time, and can thus be left in place and may be seen as an
enhancer of a traditional orodispersible fast-dissolving drug delivery
vehicle.
An oromucosal buccal film is expected to have a longer residence
time on the oral mucosa than a fast dissolving oral film, properties that
can be controlled by the hydration, swelling, and dissolution processes
of the matrix polymers (Smart, 2005). Crucial points for buccal films
are their wetting and disintegration properties, effect of mucoadhesion,
and for enhancement of a drug delivery platform, also, solubilising of a
poorly soluble drug (Fonseca-Santos and Chorilli, 2018; Smart, 2005).
In this study, we propose the use of a graft copolymer, Soluplus®,
known for its capacity to solubilise poorly soluble drugs and form
amorphous solid dispersions (BASF, 2010), as a film former and a novel
drug delivery formulation as basis for mucoadhesive buccal film. So-
luplus® was originally developed for hot-melt extrusion and to form
amorphous solid dispersions (Hardung et al., 2010). It has a poly-
ethylene backbone with one or two grafted sidechains consisting of
vinyl acetate randomly copolymerised with vinyl caprolactam (Fig. 1).
The overall composition being 57% vinyl caprolactam, 13% poly-
ethylene glycol 6000 and 30% vinyl acetate, and the molecular weight
ranging from 90 to 140,000 g/mol (BASF, 2010). The CMC of Soluplus®
is very low (7.6 mg/L), according to the producer (BASF, 2010), and in
aqueous media it readily forms micelles, which can be used to solubilise
poorly soluble drugs. The intrinsic behaviour of Soluplus®-micelles was
recently investigated under conditions relevant for oral drug delivery
(Alopaeus et al., 2019) and CMC at 37 °C, determined through iso-
thermal titration calorimetry, was found to be 0.5 mg/mL in water. To
supplement the mucoadhesive properties, two different potentially
mucoadhesive polymers were combined with Soluplus® as well as
evaluated individually. Hydroxypropyl methylcellulose (HPMC), also
known as hypromellose, is a commonly used film former (Li et al.,
2005; Timur et al., 2019; Zulfakar et al., 2016). HPMC is known for its
mucoadhesive properties and often referred to as one of the first gen-
eration mucoadhesive polymers (Fonseca-Santos and Chorilli, 2018;
Hiorth et al., 2014; Smart, 2005). Lycoat® is a modified hydroxypropyl
pea starch, which was originally developed as a coating agent for ta-
blets and capsules, but the aqueous film properties designed for im-
mediate release might have interesting applications as film modifier in
mixed multi-polymer oral films (Nagar et al., 2011; Parissaux et al.,
2007). Starches are known adhesive polymers and different starches,
such as hydroxyethyl starch, are listed among mucoadhesive non-ionic
polymers (Fonseca-Santos and Chorilli, 2018); hence, Lycoat® should be
an interesting reference with the purpose of obtaining mucoadhesive
properties of oral films.
The overall aim of the study was to design a new mucoadhesive oral
film formulation utilising the solubilisation capabilities of Soluplus®
micelles. The novel formulation should provide the stability and user-
friendliness of a dry oral film, assuring the mucoadhesive properties
and enabling an increased residence time on the buccal mucosa. Our
hypothesis is that Soluplus® in the film will disperse and form micelles
upon contact with water. In the amount of saliva accessible, the con-
centration is expected to be above CMC. A rapid hydration of the film
and disintegration of the Soluplus® film is desirable in order to release
the micelles containing drug into the formed hydrogel scaffold, thereby
providing the drug in a solubilised form that can produce a con-
centration gradient over the buccal epithelium ensuring passive diffu-
sion over the barrier. At the same time, increased mucoadhesion is
necessary for the micelles to remain in close proximity to the epithe-
lium for a prolonged period to increase the total amount of drug that
can permeate. The film undergoes a transformation from a dry, solid
and stable formulation into a functionalised advanced delivery system
upon application, i.e. contact with water or saliva. To the best of our
knowledge, this is the first time the graft co-polymer, Soluplus®, has
been combined with a mucoadhesive polymer to form a self-dispersible
functionalised advanced buccal drug delivery system. This combination
of a solubilising agent as the film matrix with a polymer that aids in
forming a hydrogel scaffold and hinders too fast erosion, gives a novel
formulation that acts like a combination of a fast dissolving or-
odispersible film and buccal formulation intended for extended release,
combining the best qualities of both formulation types. In order to gain
a mechanistic understanding of the film formulations and their inter-
actions with moisture and liquid, their mechanical and mucoadhesive
properties as well as the permeability of a BCS class IV drug across
buccal cell layers, films based on individual and polymer combinations
were evaluated. Furosemide was selected as a BCS class IV model drug
(Granero et al., 2010).
2. Materials and methods
2.1. Materials
Furosemide was purchased from Fagron (Copenhagen, Denmark).
Soluplus® was kindly donated by BASF (Ludwigshafen, Germany).
HPMC, with a viscosity grade of 5 cPs, was purchased from Norsk
Medisinaldepot AS (Oslo, Norway) and glycerol from
Apoteksproduksjon AS (Oslo, Norway). Modified hydroxypropyl starch:
Lycoat® RS720, was kindly gifted from Roquette Pharma (Lestrem,
France) and is referred to as Lycoat®. Methanol (MeOH) of high-per-
formance liquid chromatography (HPLC) grade (Merck, Darmstadt,
Germany) was used. The water was purified by the Milli-Q® integrated
water purification system for ultrapure water (Merck Millipore,
Darmstadt, Germany) and is referred to as Milli-Q water. All salts for
buffer preparation were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Medium for cell growth Dulbecco's Modified Eagle's Medium
with high glucose (DMEM), inactivated foetal bovine serum, non-es-
sential amino acids, penicillin and streptomycin (Pen-Strep) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) in the culture of HT29-
MTX cells. For the culture of TR146 cells all medium for cell growth
was purchased from Invitrogen Corporation (Life Technologies, S.A.,
Madrid, Spain) as was Hanks Balanced Salt solution (HBSS). All theFig. 1. The structural formula of Soluplus®.
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other chemicals and solvents were of reagent grade or HPLC grade.
0.01M phosphate-buffered saline (PBS), pH 7.4 was prepared from
tablets acquired from Sigma-Aldrich (St. Louis, MO, USA) and Milli-Q
water. For analyses where larger quantities of PBS were needed, the
medium was prepared according to European Pharmacopoeia (Ph.Eur.)
Chapter 4.1.3. In addition, phosphate buffer with a pH of 6.8 for the
mobile phase was prepared according to Ph.Eur. Chapter 4.1.3. Saliva
substitute (pH 6.8) was prepared according to the Documenta Geigy
Scientific Tables (Diem and Lentner, 1970) of natural saliva contents,
and was prepared as a solution of 0.21 g/L of NaHCO2, 0.43 g/L NaCl,
0.75 g/L KCl, 0.22 g/L CaCl2 • 2H2O, 0.91 g/L NaH2PO4 • H2O, and was
prepared both with and without 3% (w/w) porcine mucin (type II,
Sigma Aldrich, St.Louis, USA).
2.2. Film preparation and compositions
2.2.1. Solvent casting and evaporation
In short, the film forming polymer was dissolved in Milli-Q water
and films prepared by the solvent casting method. In the films con-
taining furosemide, the drug was solubilised in Soluplus® overnight,
before the rest of the ingredients were added and the film cast.
Solutions were cast on a levelled glass plate of the film casting appa-
ratus (Coatmaster 510 ERICHSEN GmbH & Co. KG, Hemer, Germany),
using a casting knife with a gap height of 1000 µm. To allow easy re-
moval of the dry film, cellophane (Panduro AS, Gressvik, Norway) was
used on top of the glass plate as release liner. The films were allowed to
dry in ambient conditions for 24 h before cutting into square pieces,
where 2× 2 cm was defined as a single-unit dose. The film pieces were
then stored in a desiccator at RH of 33.2–33.6% (oversaturated MgCl2•6
H2O solution) and room temperature, for a minimum of two weeks
before being used in experiments to ensure constant conditions and
homogeneous humidity throughout the batch parallels.
2.2.2. Film formulation optimisation
In addition to films containing Soluplus® as single polymer, films
containing an additional polymer were prepared. Based on their po-
tentially bioadhesive properties, HPMC and Lycoat® were chosen as the
additional polymers. Optimal formulations were developed by testing
different ratios of Soluplus® paired with either of the mucoadhesive
polymers, HPMC and Lycoat®. Glycerol was added as plasticiser.
Separate films of each of the bioadhesive polymers were prepared as
controls, and a commercially available over the counter (OTC), fast
dissolving oral film was also included. Table 1 shows the composition
overview of the optimised film formulations chosen for further
experiments, before solvent evaporation as well as the theoretically
estimated contents after drying was complete. The commercial re-
ference (F6 reference) was Melatonin Ratiopharm, a pullulan-based
rapidly dissolving oral film (Ratiopharm, 2019).
2.3. Film characterisations
2.3.1. Mass, thickness, uniformity and morphology
Basic film characterisations were performed on single-unit doses.
The thickness of the film samples was measured using a micrometer
screw (Mikrometer Cocraft, Clas Ohlson, Sweden) with a measuring
range of 0 – 25mm and resolution of 0.01mm (n=6). Residual
moisture content for dried films that had been kept in desiccator for a
minimum of two weeks was measured with an IR moisture analyser
(MA30 Sartorius, Goettingen, Germany). The samples were heated for
30min at 120 °C and all samples were tested in triplicate. The mass was
measured using an Sartorius Research R160P balance (Richmond
Scientific Ltd., England) and uniformity of mass evaluated according to
the monograph for tablets (uncoated or film coated) of 80mg or less
(Ph.Eur. Chapter 2.9.5), since there are no official monographs speci-
fically for the test of uniformity of mass for oral films. Briefly, 20
randomly selected single-unit doses were weighed and the average and
standard deviations calculated, then the percentage deviation of each
individual mass from the average mass was calculated. According to the
monograph, not more than two of the individual masses should deviate
from the average mass by more than 10% and none should deviate by
more than twice that percentage, i.e. 20%.
The surface and morphology of the films were visualised with
Scanning Electron Microscopy (SEM). Films were fixed on aluminium
stubs with double-sided carbon tapes and then covered with a thin
conductive gold layer using a BAL-Tec SCP 050 Sputter Coater (Leica
Instruments, Wetzlar, Germany). Coated samples were investigated
with a Phenom World XL (Phenom-World B. V., Eindhoven, The
Netherlands) using the Backscatter detector and a working voltage of
10 kV.
2.3.2. Quantification of content and content uniformity
The quantification of furosemide was done by HPLC-UV/VIS as
previously published (Alopaeus et al., 2019). Briefly, a reversed-phase
column (Nova-Pak®, C18, 4 μm, 3.9×150mm, Waters, Wexford, Ire-
land) was used, and the mobile phase consisted of filtered (0.45 μm)
phosphate buffer with a pH of 6.8 (see Section 2.1): MeOH (70:30 v/v).
The injection volume was 10 µL, flow rate 1mL/min, column tem-
perature 30 °C, and detection wavelength 276 nm. The retention time
for furosemide was approximately 8min, and the calibration curve was
in the range of 0.1–5.0 μg/mL (R2 ≥ 0.99). For the quantification of
samples containing Soluplus®, it was essential to make sure that the
polymer was sufficiently washed off the column between injections by
regularly running a washing program.
Drug content and content uniformity was evaluated with a slight
modification to the uniformity of content monograph for tablets
(Ph.Eur. Chapter 2.9.6). Film pieces were accurately weighed and dis-
solved separately in 100mL PBS pH 7.4. Films were allowed to dissolve
under stirring and protected from light for a suitable amount of time
and contents quantified by HPLC. Film formulations F1-F3 were as-
sessed (n=10), the average and standard deviations for all formula-
tions were calculated and the results were interpreted so that no more
than a 15% deviation between samples was deemed acceptable.
2.3.3. Mechanical studies
Mechanical properties of the films were evaluated by a puncture test
using Texture Analyser Ta-XT2i (Stable Micro Systems, Godalming,
UK), equipped with a flat-faced cylindrical probe with a diameter of
7.03mm. The software supplied by the manufacturer was Exponent
version 6.1. The sensitivity of the Texture Analyser 5 kg load cell is
0.001 N. Film pieces of 2×2 cm were fixed by screws between two
Table 1
Composition of wet film formulations before casting and drying, and estimated
composition of the dry films; all amounts in% (w/w).






F4 HPMC F5 Lycoat
Composition of wet film formulation
Furosemide 0.1 0.1 0.1 – –
Soluplus® 25.0 16.0 16.0 – –
HPMC – 0.5 – 8.0 –
Lycoat® – – 0.5 – 17.0
Glycerol 3.5 3.5 3.5 2.0 3.5
Milli-Q water 71.4 79.9 79.9 90.0 79.5
Estimated composition of dry film
Furosemide 0.3 0.4 0.5 – –
Soluplus® 80.6 67.7 70.6 – –
HPMC – 2.1 – 65.5 –
Lycoat® – – 2.4 – 74.9
Glycerol 12.9 17.2 17.9 18.7 16.9
Rest moisture
content*
6.3 12.5 8.7 15.9 8.2
⁎ Determined by IR-moisture analyser.
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plates, with a cylindrical hole with an area of 38.82 mm2.
The Texture Analyser was adjusted to move the probe with a pre-
test velocity of 2.0mm/s. Measurement started when the probe ob-
tained contact to the sample surface, defined by trigger force, which
was set at 0.049 N. After that, the system started recording force and
displacement of the probe. The test speed was constant 0.1 mm/s until
the film ruptured. The maximum force to break (N) and distance (mm)
of probe movement until break was measured, and tensile strength (N/
mm2) and elongation at break (%) were calculated (Preis et al., 2014b).
All experiments were conducted at room conditions and all samples
were tested in triplicate.




where the force is the measured maximum force at film rupture (N) and
area is the probe contact area with the film (mm2).












where a represents the radius of the film in the sample holder opening
called initial length (a=6.985mm), a’ represents the initial length of
the film sample that is not punctured by the probe (a’=3.47mm), b
represents the penetration depth of the probe (i.e. distance or dis-
placement) and r represents the radius of the probe (r=3.52).
2.3.4. Wettability
The wettability was estimated by measuring the contact angle of a
droplet (1 µL) of bidistilled water towards each of the film formulations
(F1-F6) at ambient conditions using a manual contact angle microscope
Type G1 from Krüss GmbH (Hamburg, Germany). Since the films were
relatively hydrophilic and started swelling very quickly and the reading
was performed manually, the experiment had to be conducted fast and
in a standardised manner, i.e. reading 3 s after application of the dro-
plet. To obtain a robust observation, twenty measurements were per-
formed for each film formulation. The mean and standard deviation
were calculated.
2.3.5. Dynamic vapour sorption (DVS)
The behaviour of the films at defined relative humidities (RH) was
investigated with a DVS-Resolution from Surface Measurement System
Ltd (London, UK), which measures humidity-dependent mass change.
The respective moisture sorption isotherms were studied at 25 ± 1 °C
and 37 ± 1 °C for an increase of p/p0 from 0.0 p/p0 to 0.9 p/p0 in steps
of 0.1 p/p0 followed by a decrease to 0.0 p/p0 as described by
Mönckedieck et al. (2017). The moisture content was kept stable for up
to 360min to allow equilibration, until the change in mass was less
than 0.005%/min. Finally, the cycle was repeated to enable statements
on water uptake and possible crystallisation event occurring because of
the applied stress. Film samples of approximately 5× 5mm were
placed in the microbalance in a position allowing water vapours to
access the film from both sides. The moisture sorption and desorption
isotherms were plotted for each temperature. All formulations (F1-F6)
were evaluated at both temperatures.
2.3.6. Swelling and erosion
A film piece (2×2 cm) was weighed (initial weight W0) and placed
in a dry beaker. 1 mL simulated saliva (pH 6.8) was added on the film
with a pipette to allow the film to swell and/or erode. At regular time
intervals, the excess of water not absorbed by the film was carefully
removed, and the wet film and beaker was weighed (Wt). Then more
simulated saliva was added to continue the analysis, the added amount
varied by film and time, as enough was added to saturate the film
surface but not more that it would run over and wet the beaker. From
the weight of the swelling film at different time points, the swelling and
erosion could be estimated and Wt/W0 was plotted as a function of
time. All formulations were tested in triplicate.
2.3.7. Disintegration
Two different methods of determining disintegration were used. The
first method, petri dish method was as follows; films were placed in a
petri dish and 3mL of simulated saliva (pH 6.8) was added. The petri
dish was shaken at a constant speed (200 rpm) to allow the irrigation
media to rinse over the film. The endpoint was set when disintegration
of the film matrix was observed.
The second method, the TA-XT2i Texture Analyser method, was
executed using a flat-faced cylindrical probe and the film mounted as
described for the puncture test (see 2.3.3). Briefly explained, 200 µL of
simulated saliva (pH 6.8) was pipetted onto the film; the lag time of 5 s
after test start before probe started moving was used to allow the liquid
placement. The probe was programmed to stop at target distance
(5mm) and monitor the force throughout the test. The typical force vs.
time profile showed that initially the force would increase before the
wetting of the film resulted in reduction of the force as the film disin-
tegrated and finally come down to the baseline when film disintegration
was complete. Endpoint of disintegration was defined at the time when
the probe returned to a force of 0.03 N. This specific force was chosen,
because according to studies, 0.03 N is the minimal force exerted by the
human tongue when licking over a probe (Preis et al., 2014a).
2.3.8. Dissolution and re-micellisation
A simple dissolution study was performed on films F1-F3. A film
piece (2× 2 cm) was weighed and added in a 100mL beaker with
50mL pre-warmed PBS at 37 °C. The films were allowed to dissolve
freely in the media under constant shaking (150 rpm) in a temperature-
controlled environment (Environmental Shaker-Incubator ES-20,
BioSan, Latvia). The samples in the beakers were not shaken or stirred
in any other way than the natural movement by the shaker. Samples of
1mL were taken out at set time points and aliquots diluted suitably for
HPLC content determination as described above.
The rest of the sample was used to determine Z-average, which was
interpreted as estimated micelle size (nm) and polydispersity index
(PDI) using dynamic light scattering (Zetasizer Nano Series, Malvern
Instruments Ltd., Malvern, UK). Values were derived from average of
three subsequent runs with 10 measurements each. Samples were run in
triplicate at 25 °C with 173° backscatter angle.
2.4. Mucoadhesion studies
2.4.1. Interaction with mucin-dispersion
A simple mucin-interaction test was conducted as described by
Hagesaether et al. (2009). Briefly, 50 µL simulated saliva with 3% (w/
w) porcine mucin was evenly spread on the top of two different pieces
of filter papers with an inert backing layer (WhatmanVR Benchkote,
Chicago, USA). The pieces of filter paper had dimensions of
1.5× 1.5 cm. Both pieces were attached with double sided adhesive
tape; one of them was placed on a lower stationary part of a TA-XT2i
Texture Analyser), and the other was attached to a flat, upper, movable
probe. A film piece of 1×1 cm was placed on the lower paper. Based
on previous work, a preload-force of 200 g for 100 s was applied before
the upper probe was lifted off at a speed of 0.01mm/s at which the
force of detachment was documented. The same was done for simulated
saliva, without the addition of mucin, to distinguish between the un-
specific adhesion (no mucin interaction) and general adhesion (with
mucin interaction). Measurements were repeated 10 times for each film
sample (F1-F6), both with and without mucin interaction. The dis-
placement and force of detachment were recorded. Based on the force
vs. time curve obtained, the peak force (Fmax, g) and work of adhesion,
i.e. the area under the peak (AUC, g/s) were obtained.
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2.4.2. Mucus-producing HT29-MTX cells as mucosal surface
Instead of buccal mucosal tissue from slaughtered animals, we uti-
lised living mucus-producing cells from the HT29-MTX cell line, kindly
provided by Dr. Thécla Lesuffleur (INSERM UMR S 938, Paris, France).
These mucus-secreting cells were originally adapted and cultured for
several passages in a medium containing 10−6 M methotrexate (MTX)
and reversed for several passages in a drug-free medium
(Lesuffleur et al., 1990, 1993). They do not need to be maintained in
media containing MTX in order to differentiate into a mixed population
of mucus-secreting goblet cells and enterocytes after confluency. The
cells used in this study were from passages 27–28. The medium for cell
growth was Dulbecco's Modified Eagle's Medium with high glucose
(DMEM), containing L-glutamine, sodium pyruvate and phenol red with
a pH in the range of 6.8–7.2 (sodium bicarbonate buffer), which was
further supplemented with 10% inactivated foetal bovine serum, 1%
non-essential amino acids, penicillin (100 units/mL) and streptomycin
(100 μg/mL).
The HT29-MTX cells were seeded at a density of 2.4× 104/cm2 in
petri dishes with a growth surface of 55 cm2 and grown for 21 days to
allow the cells to differentiate into mucus producing goblet cells and a
distinct mucus layer to form on top of the cell monolayer. The cells
were incubated at 37 °C under an atmosphere of 5% CO2. For the pre-
servation, the cells were passaged before reaching 80% of confluency
with a solution of trypsin-EDTA. The medium was changed 3 times
weekly. The cell monolayer integrity as well as the mucus layer were
inspected with a microscope before use in the retention experiments
(see 2.4.3).
2.4.3. Retention model using mucus-producing cells
The retention of the formulation to a mucosal surface was evaluated
in a modified version of an oral cavity model previously described by
Madsen et al. (2013). Mucus-producing cells grown in a petri dish were
used as the mucosal surface and a film piece (2×2 cm) was placed on
the mucus on top of the cell monolayer. To simulate the flow of saliva
the formulation was exposed to a constant flow of PBS (pH 7.4) rinsing
over the film. The PBS was collected at the outlet, and samples were
withdrawn at predetermined time points and the drug content quanti-
fied. The model was used to estimate the retention of the drug to the
mucosa and was taken as an indication of mucoadhesiveness of the film
formulation.
The retention model was set up using a water-bath GD100 (Grant
Instruments, Cambridge, UK) to warm PBS, which was transported
through a high-precision multichannel dispenser pump (ISMATEC
ISM931C, Wertheim, Germany) through pipette tips fitted onto a plat-
form situated in a closed humidity chamber. The PBS rinsing over the
mucosa was 37 ± 1 °C and the humidity and temperature in the
chamber was kept at > 80% and 37 ± 1 °C, respectively. The PBS
rinsing over films came from 4 individual nozzles to spread the media
equally over the whole formulation. Each nozzle had a flow rate of
0.4 mL/min equalling a total flow rate of 1.6mL/min for the set-up.
Film formulations F1, F2 and F3 as well as free drug (furosemide dis-
solved in PBS) were tested in triplicate.
2.5. Transepithelial drug diffusion study using TR146 cells
2.5.1. Cultivation and maintenance of the cells
Permeability across buccal membrane was assessed using TR146
human buccal epithelium cell line culture (ATCC; American Type
Culture Collection, Barcelona, Spain). TR146 cells were chosen to
mimic stratified epithelium of human buccal mucosa (Castro et al.,
2018; Jacobsen et al., 1995; Nielsen and Rassing, 2000). TR146 is a cell
line originating from a neck node metastasis of a human buccal carci-
noma (Rupniak et al., 1985) and are known to express characteristics of
human buccal epithelium, such as no tight junctions and absence of
complete keratinisation (Jacobsen et al., 1995). The permeability of
furosemide from formulations F1-F3, as well as free drug as control,
was assessed in Falcon® Transwell inserts (PET, pore size 3.0 µm), using
6-well plates. TR146 cells (passage P19) were seeded with a density of
2× 105 cells/well on the inserts and medium was changed three times
weekly for 24 days of culture before using the cells in the experiment.
The growth medium used was DMEM, containing L-glutamine, sodium
pyruvate and phenol red with a pH in the range of 6.8–7.2 (sodium
bicarbonate buffer), which was further supplemented with 10% in-
activated foetal bovine serum, 1% non-essential amino acids, penicillin
(100 units/mL) and streptomycin (100 μg/mL). Cells were maintained
in an incubator (CellCulture® Incubator, ESCO GB Ltd., UK) at 37 °C and
5% CO2. Trans-epithelial electric resistance was monitored using an
EVOM epithelial voltohmmeter equipped with chopstick electrodes
(World Precision Instruments, Sarasota, FL, USA), starting from day 7
and throughout the growth period, as well as during and after the
permeability study. The TEER values of the cell layers were measured
before cell medium was changed to monitor the evolution of con-
fluence. Only wells with sufficient and stable values after 24 days of
culture were used in the experiment.
2.5.2. Permeability studies
For the permeability study, film pieces equivalent to 200, 210 and
220 µg of furosemide content for films F1, F2 and F3, respectively, were
added to the apical side, where 1.5mL of HBSS had been added re-
placing the growth media. HBSS is a buffered salt solution designed to
maintain the solution pH at a physiological interval (7.1–7.4). Free drug
was in concentration equivalent of 500 µg per well, also dissolved in
HBSS. The medium from the basolateral side was replaced with pre-
warmed HBSS (2.5 mL). The plates were incubated under stirring
(100 rpm) at 37 ± 1 °C. Samples of 200 µL were withdrawn at 15, 30,
45 and 60min from the basolateral side, with pre-heated fresh media
added every time to replace the withdrawn volume maintaining sink-
conditions. After finished experiment, the samples withdrawn from the
basolateral side, and a sample from the apical side, were suitably di-
luted and analysed using HPLC-UV/VIS. Moreover, the cells were sub-
jected to lysis using 1% Triton-X in order to quantify the furosemide
adsorbed to the cell surface or internalised by TR146 cells. Briefly, the
furosemide quantification was performed in a Merck Hitachi LaChrom®
system (Merck Millipore, NJ, USA) equipped with a D-7000 Interface, a
L-7455 Diode Array Detector, a L-7200 Autosampler, and a L-7100
Pump. Furosemide samples were injected (20 μL) on a LiChrospher®
100 RP-18 (125×4mm, 5 μm, Merck Millipore, NJ, USA) with a
LiChrospher® 100 RP-18 guard column (4×4mm, 5 μm, Merck
Millipore, NJ, USA) and mobile phase consisting of acidified water (pH
5.5) and 2-propanol (70:30, v/v) at a flow rate of 1.0mL/min.
Furosemide elution was monitored at 238 nm.
The flux (J) and the apparent permeability coefficient (Papp) was
calculated for each permeability experiment and each film formulation
was tested in triplicate. The reported values are the average of the in-
dividually calculated Papp for each parallel. The flux was calculated as
(Di Cagno et al., 2015) the slope of the linear regression of the cumu-
lative permeated drug plot, normalised by the surface area (A), as ac-
cording to Eq. (3):
=J dQ
A x dt (3)
where dQ is the fractional amount of permeated drug expressed as
moles, and dt is the time interval expressed in seconds. The Papp was
calculated by normalising the flux (J) over the total concentration of




All the values are shown as mean± standard deviations. Where
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applicable, a one-way ANOVA with Tukey's post hoc test was applied to
determine statistical significance. All the analyses were performed
using the software program GraphPad Prism 8® (Graphpad Software
San Diego, CA, USA) with the statistical significance set to p≤ 0.05.
3. Results and discussion
3.1. Optimisation of Soluplus®-based films
Soluplus® in water produced thin-flowing micellar suspensions of
low viscosity up to concentrations between 15–20% w/w
(Alopaeus et al., 2019). The viscosity or flow properties of the film
formulation is an essential parameter allowing the preparation of films
with the solvent casting method using the Erichson film applicator, i.e.
casting on a glass plate with no limiting walls (Krampe et al., 2016).
Formulations with too low viscosity would flow off the plate whereas
too high viscosity limits even spreading with the knife. Aqueous Solu-
plus®-dispersions with a concentration of 25% w/w were found em-
pirically to have suitable properties as a single polymer. However, So-
luplus® in combination with another polymer formed dispersions with
high viscosity. Therefore, various concentrations of Soluplus® in com-
bination with each of the hydrophilic polymers HPMC or Lycoat® were
screened. Addition of concentrations above 1% of the mucoadhesive
polymers led to phase separation as determined by visual inspection.
The combination of Soluplus® 16% w/w with 0.5% w/w of either of the
additional polymer showed suitable casting properties and no phase
separation occurred either in wet or in dried condition.
Glycerol was added to the film formulations as plasticiser, which are
typically added in films up to 20% (Arya et al., 2010). The glycerol
content was selected based on the texture and mechanical properties to
allow easy handling. Concentrations over 6% for single polymers and
over 3.5% for Soluplus®-based formulations resulted in sticky film
surface and highly plastic films, whereas too low concentrations gave
brittle films that were difficult to cut or handle. Finding the right gly-
cerol level was more challenging for Soluplus®-containing films than for
the HPMC (F4) or Lycoat® (F5) reference films. It should be mentioned
that residual moisture content also acts as plasticiser in the films, and
the Soluplus®-based films dried more slowly than their single-polymer
references. To avoid adding too much glycerol to the film formulations
and obtaining highly plastic films, the films were cut into single dose-
units while still in the drying process. This means that they were cut
after drying overnight and transferred to a humidity-controlled de-
siccator for the stabilising of the moisture content.
Furosemide was selected as a model drug because it is a BCS class IV
drug with poor solubility and permeability (Granero et al., 2010), and it
is on WHO Model List of Essential Medicines for Children (WHO, 2017).
The amount of drug that could be solubilised into the Soluplus®-con-
taining films was selected based on the solubilising capacity of Solu-
plus® dispersion, determined in an earlier study (Alopaeus et al., 2019).
Considering that the solvent loss on drying can trigger re-crystallisation
of the drug, the solubilisation of dehydrated micelle-dispersions would
be limited. It was decided to add the same amount of drug to all film
formulations since it was challenging to predict the final concentration
in the film prior to preparation. The optimised formulations and the
estimated composition of the resulting dry films are found in Table 1.
3.2. Film characterisations
All films were cast with the same gap height; therefore, the wet film
thickness was the same (1000 µm) for all formulations. After drying, it
could be noted that the edges of the large film sheet had a larger var-
iation in the film thickness as compared to the central part. Therefore, a
minimum of 2 cm of the outer edges was removed before single units of
2× 2 cm, defined as single dose, were cut. Basic film characterisations
showed that all film formulations differed relative to each other in the
mass, film thickness and drug content per single unit-dose (Table 2).
The thickness spanned from around 70 µm to around 235 µm. Films
with Soluplus® as the single polymer gave the thickest final films. So-
luplus® also had great influence on the mixed polymer films; they were
considerably thicker than single-polymer films of HPMC or Lycoat®.
Weight and thickness were mostly correlated, except for F2 and the
reference.
All films except F2 passed the Ph.Eur. requirements for uniformity
of mass, when applying the criteria for the test intended for small ta-
blets (Ph.Eur. Chapter 2.9.5), in the lack of recognised criteria for oral
films. The drug content correlated well with the estimated theoretical
content (Table 2); however, it was different per dose for the three So-
luplus®-based films due to the differences in the film composition and
weight/thickness ratio. The drug content was within the requirements
for uniformity of dosage units (Ph.Eur. Chapter 2.9.6.) for films F1 and
F3, but for F2 the variance was again too large to pass the requirements
for tablets with low dose. Likely, this is related to the fact that the
weight and thickness were not completely homogeneous across the
whole film for F2 and thus these variations naturally occur. To reduce
the variation, an even larger outer part could have been removed and
discharged.
All films were transparent with a non-sticky surface and smooth
appearance (Fig. 2A-F). The scanning electron micrographs in Fig. 2
showed that they had a flat and smooth, none-porous surface, only the
commercial reference (Fig. 2F) had a slightly different morphology.
These films were white and appeared more fibrous or phase separated
when examined with the naked eye, and the fibrous structure could also
be recognised in SEM.
3.3. Mechanical properties
A buccal film formulation should have mechanical properties that
allow easy handling and placing on the buccal mucosa. Suitable me-
chanical properties would be intermediate strength and certain flex-
ibility to promote and facilitate interaction with the mucosa. Since it is
difficult to quantify these expectations, a commercially available re-
ference was included in the test set (F6). The Soluplus® film (F1) was
among the strongest with the second highest tensile strength, but it
exhibited relatively low flexibility determined as elongation at break
(Table 3), at least compared to the films containing HPMC. The re-
ference films (F4-F6) were further compared to the films containing
furosemide, as the drug is not expected to have an effect on the me-
chanical properties as the amount is so low (less than 0.45 w%). For-
mulations containing HPMC, both the reference HPMC film (F4) and
Soluplus®-HPMC film (F2) were the most flexible and showed the
highest elongation at break. The Lycoat® film (F5) was hard to break
(i.e. high tensile strength) but elongation at break was very low, and
even lower when paired with Soluplus® (F3). Soluplus®-HPMC showed
relatively low tensile strength but elongation at break was even higher
than the pure HPMC. Compared to the commercial reference film (F6)
Table 2
Overview of film thickness (n=10), mass of single unit-dose (n=20) and
furosemide content per single unit-dose (n=10) of all film formulations
(mean± SD).
Film formulation Film thickness
(µm)




F1 Soluplus 235±3 134.3 ± 10.1 404 ± 28
F2 Soluplus-
HPMC
175 ± 10 124.1 ± 13.0 602 ± 124
F3 Soluplus-
Lycoat
213 ± 6 104.7 ± 8.1 499 ± 64
F4 HPMC 71 ± 7 54.8 ± 4.0 n.d.
F5 Lycoat 130 ± 8 73.3 ± 4.6 n.d.
F6 reference 126 ± 8 45.7 ± 2.5 n.a.
n.d.: contained no drug, n.a.: not available (commercial reference with different
drug).
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the mechanical properties of all Soluplus® containing films were in
comparable range, except that the elongation to break of the combi-
nation with HPMC (F2) was significantly higher. However, the cutting
and handling properties of the Soluplus®-HPMC film (F2) was not im-
paired by the higher elasticity. Preis et al. (2014b) investigated the
mechanical properties of commercial films and found tensile strength
values ranging between 0.08 and 0.49 N/mm2, and slightly higher (up
to 1.02 N/mm2) for the films made in their lab. Elongation was not
found to be a crucial parameter, which correlates well with our findings
of elongation at break in Soluplus®-based film formulations; where
Fig. 2. SEM images of the surface of film formulations A:F1, B:F2, C:F3, D:F4, E:F5 and F:F6, the magnification is 1500x and the bar indicates 50 µm.
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values ranged from ca. 2% for F3 to over 30% for F2 as this could not be
correlated with any of the other film properties. The amount of glycerol
is known to play a role on the mechanical properties results as this
excipient acts as a plasticiser (Aulton et al., 1981), and is added to the
formulation to ease handling. Residual moisture content will also act as
a plasticiser, therefore, the total amount of plasticiser can be more
challenging to estimate, and it is of crucial importance that the films are
equilibrated under similar RH prior to tests on mechanical properties.
Adding a hygroscopic polymer, such as HPMC, will result in increased
flexibility as could be seen with film F2. All Soluplus® containing films
were concluded to have acceptable mechanical properties for the use as
a buccal delivery system, however, the higher flexibility of the films
containing HPMC (F2 and F4), are likely to be better received from a
patient-centric view, as this enhances comfort of the formulation and
might even affect the mucoadhesion through improved interaction with
mucosa.
3.4. Interactions with moisture vapour and liquid
Dynamic vapour sorption analyses were conducted to determine the
moisture sorption and desorption capacities of the various formula-
tions. The films were exposed to two subsequent cycles of changing RH
from 0% to 90% to 0% RH in steps of 10% RH during DVS analysis.
Fig. 3 shows the entire cycle of water sorption and desorption taking
place during DVS measurements for a Soluplus®-HPMC film. The
sorption capacity (% mass change) was dependent on the composition
of the formulation, the relative humidity and the time. The time it took
to complete the entire measuring cycle was different for the different
film compositions. The sorption isotherms of all film formulations at
25 °C can be seen in Fig. 3. Water sorption isotherms of all films initially
showed a moderate increase in moisture content with a progressive
increase in relative humidity up to around 40%. This was followed by a
rapid increase in water absorption for higher RH. For hygroscopic films,
this is expected behaviour. The HPMC film showed the highest sorption
of water, likely due to an increased number of hydrogen binding sites
for water on the hydrophilic polymer chain (Li et al., 2005). In addition,
in the mixed films of Soluplus®-HPMC films, the difference is more
pronounced than with Lycoat® (Akhtar et al., 2013).
The results obtained at 80 ± 2% RH (indicated with a red line in
Fig. 4) and 25 ± 1 °C were used to compare the hygroscopicity of the
different film formulations. Table 4 summarises the percentage mass
increase observed at 80% RH for the two temperatures 25 ± 1 °C and
37 ± 1 °C. All tested oral films showed a mass increase of more than
15% after equilibration in 80% RH at 25 °C, and would therefore be
classified as very hygroscopic according to the Ph.Eur. (Chapter 5.11.).
Film formulations F1 and F6 showed very similar values for the two
Table 3
Mechanical properties obtained by Texture Analyser (n=3) (mean±SD).
Film formulation Fmax (N) Displacement (mm) Tensile strength (N/mm2) Elongation at break (%)
F1 Soluplus 26.00 ± 11.25 1.68 ± 0.46 0.67 ± 0.29 5.75 ± 2.86
F2 Soluplus-HPMC 13.40 ± 1.23 4.39 ± 0.78 0.35 ± 0.03 30.69 ± 8.58
F3 Soluplus-Lycoat 8.29 ± 1.44 1.0 ± 0.13 0.21 ± 0.04 2.12 ± 0.51
F4 HPMC 44.11 ± 9.47 4.01 ± 0.59 1.14 ± 0.24 26.41 ± 6.41
F5 Lycoat 34.22 ± 9.73 1.52 ± 0.25 0.88 ± 0.25 4.62 ± 1.43
F6 reference 21.19 ± 0.78 1.42 ± 0.09 0.55 ± 0.02 4.03 ± 0.51
Fig. 3. DVS analysis of film sample of Soluplus®-HPMC film. Two cycles from 0% to 90% RH in steps of 10% RH at 25 °C. The blue line denotes the target RH profile
(secondary axis), whereas the red line shows the% changes in the film mass as a result of change in% RH (primary axis).
J.F. Alopaeus, et al. European Journal of Pharmaceutical Sciences 142 (2020) 105142
8
tested temperatures, whereas film formulations F2 - F5 showed de-
creasing mass increase-values with increasing temperature. The largest
change can be seen in the pure HPMC film, which is also the most
hygroscopic of the tested materials. Since HPMC is a derivative of
cellulose, obtained by substituting hydroxypropyl and methyl groups to
primary and secondary hydroxyl groups, three factors, namely, methyl
content, hydroxypropyl content, and molecular weight control the final
properties and behaviour of HPMC (Li et al., 2005). The molecular
weight determines the viscosity in aqueous solution, with low mole-
cular weight also correlating to good water solubility and good film-
forming properties. HPMC and Lycoat® are thermoresponsive polymers
with low gelation temperatures (and low critical solution temperature)
and at higher temperatures, the sol-gel transformation has a role in the
number of free binding points available for water molecules to bind,
hence lower absorption at higher temperatures as the moisture sorption
is temperature dependent in thermoresponsive gels (Joshi, 2011). For
Soluplus®, the temperature has less of an effect as the mechanism is
different. Gelation mechanism and sol-gel transformation in Soluplus®
is an effect of increased entanglements of Soluplus® micelles at in-
creasing temperatures, which does not correlate to increased moisture
absorption (Alopaeus et al., 2019; Tanida et al., 2016; Taylor et al.,
2017).
Another way to investigate the moisture interaction with the film is
to determine the contact angle of a droplet of water on the dry film
surface. Contact angle measurements indicate the degree of wetting
when a solid and a liquid interact. Theoretically, small contact angles 〈
90° correspond to high wettability and large contact angles 〉 90° cor-
respond to low wettability. Generally, all tested film formulations ex-
hibited contact angles of far less than 90°, indicating good wettability
properties (Fig. 5). The highest contact angle was found for the single-
polymer Soluplus® film (F1) at 52.0°± 2.9, which was in the same
order of magnitude as reported for the Soluplus®-indomethacin solid
dispersion at 54.9°± 8.0 (Semjonov et al., 2018). The authors further
showed that formation of solid dispersions of Soluplus® increased the
wettability of the polymer, compared to the dry solid in powder form.
The contact angle of the hydrophilic polymer films, HPMC (F4), Lycoat®
(F5) and pullulan (F6), were significantly lower than the Soluplus® film
(p<0.05). This is in agreement with the DVS findings. The water
sorption and the wettability of hydrophilic materials are linked to the
hydrogen bonding ability of these biopolymers (Dahlberg et al., 2010).
The lowest contact angle was found for Soluplus®-HPMC (F2) film at
24.5°± 6.9. It is notable that the Soluplus®-polymer combination films
(F2 and F3) displayed a synergistic effect where mixing Soluplus® with
a hydrophilic polymer resulted in better wetting capacity (reduced
contact angle) then either component had on its own. It is also known
that surface topology might have an effect on the contact angle, where
two phenomena: spreading and absorption, will interplay (Farris et al.,
2011). However, according to the SEM images and morphological in-
spection of the films, all films had a smooth surface with similar to-
pology; thereof this is not likely to be an issue here.
The next step was to look at the behaviour of the films in contact
with aqueous liquid. The swelling-erosion test gives an indication of the
degree of moisture uptake in the film before erosion starts
(Adrover et al., 2018). A fast disintegrating film formulation would be
expected to have a high and fast uptake but erosion starting very ra-
pidly. A film meant for buccal administration, on the other hand, will
have desirable properties of relatively good wetting behaviour and
moisture uptake, but erosion should be slow, so the film matrix retains
its shape and can stay in place for longer (Preis et al., 2013). Fig. 6
shows the results from the swelling-erosion test in simulated saliva.
Typically, the weight of the film initially increased until dissolution
occurred and the film weight decreased because of the eroded material
Fig. 4. Sorption isotherms for the investigated film formulations. Red line indicate the% mass change after equilibration at 80± 2% RH and 25±1 °C, i.e. the
conditions for determining hygroscopicity according to Ph.Eur. (Chapter 5.11).
Table 4
Percentage mass increase after equilibration at 80% RH for all film formulations
(values are the arithmetic mean of the two cycles).
Film formulation dm (%) at 25 °C dm (%) at 37 °C
F1 Soluplus 18.27 18.47
F2 Soluplus-HPMC 20.03 17.25
F3 Soluplus-Lycoat 19.25 16.58
F4 HPMC 36.37 18.78
F5 Lycoat 25.08 19.98
F6 reference 22.10 22.20
Fig. 5. Contact angle determined with a droplet of bidistilled water on the film
at ambient temperature. Mean± SD (n=20).
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was removed together with the excess of liquid. The commercial re-
ference (F6), which is a rapidly dissolving orodispersible film, showed
typical properties with rapid increase in weight and then quickly
eroding until completely disintegrating within minutes. The Lycoat®
reference film (F5) had the same profile but the weight gain ratio was
not as high, whereas HPMC reference film (F4) had similar swelling
capacities as F5, but the erosion did not happen as fast, and by visual
inspection, the film was transformed into a swollen hydrogel (Li et al.,
2005). The three formulations based on Soluplus® (F1-F3) did not swell
and gain weight as much as the other film formulations, the erosion was
also a very slow process and the films retained their shape much longer
throughout the test without dissolving visibly. The good structural in-
tegrity is especially evident for the combination films, F2 and F3, which
presented very stable profiles with minimal erosion after 6min (insert
in Fig. 6). The single Soluplus® film (F1), lacked the support structure of
the combination film-forming polymer, thus dispersed in the final stage,
and was removed with the excess of liquid.
Two different types of disintegration tests were performed on all
films (F1-F6), a petri dish method and a drop method using a Texture
Analyser, respectively. The petri dish method was described in litera-
ture earlier (Preis et al., 2014c). However, since the method is highly
subjective and, similarly to the swelling erosion-test, it does not subject
the films to any mechanical stress, a more objective method was de-
veloped to evaluate how the different films disintegrated. The texture
analyser method introduces a mechanical punch and might therefore
provide information that is more relevant for the disintegration prop-
erties of a buccal dosage form. Table 5 provides an overview of the
results from the two disintegration tests. In the petri dish method the
commercial reference (F6) and the Lycoat® reference (F5) both disin-
tegrated within 30 s, which is the FDA definition of an orally disin-
tegrating tablet (FDA Guideline, 2019). The criteria is often also applied
for orally disintegrating films (Borges et al., 2015; Dixit and
Puthli, 2009; Speer et al., 2018). All Soluplus®-containing films showed
significantly longer disintegration times, from around 2.5 min up to
around 5min, depending on which of the other polymers Soluplus® was
mixed with; HPMC prolonged the disintegration time whereas Lycoat®
shortened it. This correlates well with the results from the swelling-
erosion studies where Lycoat® (F5) and the commercial reference (F6)
showed properties of rapid erosion and HPMC was observed to form a
type of hydrogel, which would show a very slow erosion pattern. In the
texture analyser method, we could determine some correlations to the
swelling/erosion and petri dish disintegration studies where the addi-
tion of Lycoat® considerably shortened the time for a film piece to
disintegrate. Soluplus® micelle formation leading to disintegration of
film is concentration-dependent; in this test-setup, there is not a lot of
liquid, which explains why the single polymer film had the longest
disintegration time. The addition of small amounts of liquid resulted in
plasticisation of the polymer rather than disintegration of the film,
which would be expected with excessive liquid. The over-plasticised
polymer could be elongated much more before the force limit was
reached; hence the observed long disintegration time for the Soluplus®
single polymer film. In this specific type of test, the addition of a hy-
drophilic polymer led to faster disintegration (F2 and F3). Some of the
films could not be measured by this method due to their rapid dissol-
ving or formation of a soft hydrogel, which was the case for the re-
ference films with single hydrophilic polymer and rapidly dissolving
commercial reference (F4-F6).
A simple dissolution study was conducted on all mixed-polymer
films (F1-F3) (Table 6). After 15 min F1 had released half of the drug
content, whereas F2 only 16% and F3 close to 65%. F1, containing only
Soluplus® showed extreme variation between the samples tested (very
high standard deviation). This can be explained by Soluplus® dispersing
rapidly into micelles, and being influenced largely from the behaviour
of the film during the test. It was observed that films that were stuck on
the beaker showed a very different release rate of the micelles as
compared to floating film that had access to water from two sides. For
formulations with HPMC added (F2) a hydrogel scaffold was formed
and a delayed dissolution occurred. Addition of Lycoat® (F3) gave a
release that was similar to F1 in the beginning, but after some minutes
the film fell completely apart and fast release was observed. The Ly-
coat® polymer did not retain the micelles in a hydrogel scaffold in the
same way as the HPMC. On the contrary, Lycoat® mixed in between the
graft co-polymer seemed to accelerate the hydration and disintegration
rate, which corresponds with the fast dissolving properties of this
polymer (Parissaux et al., 2007).
After finalising the dissolution test, all samples (solutions containing
the released micelles) were also concurrently tested to estimated mi-
celle size and polydispersity index (PDI). These results in Table 6
showed that the values corresponded well with the micelle size for
Soluplus® micelles in aqueous solution (Alopaeus et al., 2019)
Fig. 6. The results from swelling and erosion studies conducted in simulated saliva for all film formulations at ambient temperature. Films F1-F3 are also showed as a
magnified insert.
Table 5
Film disintegration studies (mean±SD; n=3).
Film formulation Disintegration time (sec)
petri dish method
Disintegration time (sec) drop
method – Texture Analyser
F1 Soluplus 210 ± 9 248 ± 3
F2 Soluplus-HPMC 277 ± 8 211 ± 8
F3 Soluplus-Lycoat 156 ± 5 135 ± 12
F4 HPMC 43 ± 5 n.a.
F5 Lycoat 27 ± 5 n.a.
F6 reference 28 ± 2 n.a.
n.a.: no available data. The method used was not suitable for this kind of film.
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confirming that as the films dissolve the micelles do not disassemble in
the process. The PDI and its standard deviation both had a trend of
reducing for samples taken after longer time, indicating that micelles
were becoming more homogeneous with a monophasic size distribution
with increasing time. Only the formulation containing HPMC showed
higher PDI in samples taken after short dissolution times, indicating
that the HPMC might connect the micelles to a certain degree, even
though the size was in the same size range. After 10min also this for-
mulation showed a size distribution below 0.1, suggesting that the
HPMC was dissolved.
Based on the behaviour in the vapour sorption, wetting, swelling,
erosion and disintegration studies it can be summarised that single
Soluplus® films, have a more hydrophobic surface with high contact
angle and lower vapour sorption isotherms as compared to mixed films
of Soluplus® with either of the hydrophilic polymers HPMC or Lycoat®.
The swelling of all Soluplus® films (F1-F3) was in the same order of
magnitude, and much lower than the more hydrophilic reference films
(F4-F6), however, the erosion and disintegration results revealed an
interesting difference; Soluplus® films (when single polymer) disin-
tegrated into micelles that after a while was dispersed into the liquid.
The mixed Soluplus® films, on the other hand, had a supportive hy-
drogel network holding the Soluplus® micelles in an intact structure.
For the Soluplus®-HPMC formulation, this structure was more stable
and not as easily ruptured by mechanical stress as observed for the
Soluplus®-Lycoat® (F3) formulation. These findings suggest that the
mixed film of Soluplus® with HPMC (F2) have properties that are highly
attractive for a buccal drug delivery system; Soluplus® micelles can be
utilised as a solubiliser and nanocarrier, contained in the scaffold cre-
ated by the hydrogel, formed from a relatively low content of HPMC
(2.1% w/w of the dry film; Table 1).
3.5. Mucoadhesive capacity
Mucoadhesion was investigated in various in vitro assays. The
simple mucin interaction studies were conducted with a Texture
Analyser to observe the interaction of the various film samples with
mucin dispersions. Fig. 7 shows the determined work of adhesion. The
ratio between general and unspecific adhesion is the estimated mucin
interaction. Formulations F3, F5 and F6 showed no mucin interaction,
which can be seen from the insignificant difference between the general
and the unspecific adhesion (p˃0.05). HPMC films (F4), Soluplus®-
HPMC mixed films (F2) as well as Soluplus® alone films (F1) showed
significantly higher general adhesion as compared to unspecific adhe-
sion (p<0.05), which indicates that these films showed high mucin
interaction. However, for the Soluplus® containing film (F1), it was
observed that the moistened film acted as a “glue” also towards the
filter when moistened with buffer, without mucin, which contributed to
a higher value for the unspecific adhesion and might be a confounder in
the determined mucin interaction. This phenomenon is illustrated in
Fig. 8, where the over-plasticising effect of the added liquid can be
observed. For the mixed Soluplus® films (F2-F3), this phenomenon was
less pronounced, but elevated unspecific binding was also observed also
for these films. The similar behaviour was not seen for films that did not
contain Soluplus®. In films with HPMC (F2 and F4), the general adhe-
sion was clearly higher than the unspecific adhesion, suggesting that
there is an interaction between the mucin and polymeric film. Gen-
erally, good wetting and swelling properties should correlate to good
mucoadhesion but only up to a certain point; polymer swelling is es-
sential for the exposure of the bioadhesive sites for hydrogen bonding
to be able to happen (Peppas and Buri, 1985). However, there is a
critical degree of hydration and too much can simply lead to disin-
tegration of the polymer network. Film formulations F5 and F6 are
made up of mostly fast disintegrating hydrophilic polymers, and as a
result, the mucoadhesive capacity in these formulations is poor and the
difference between specific and unspecific adhesion is not significant.
For mucoadhesion to happen there has to be enough contact time at the
interface of the polymer and the mucosal surface. Over-wetting and
disintegration will only lead to a formation of a slippery surface without
mucoadhesion (Smart, 2005). In the mixed film with Soluplus® and
Lycoat® (F3), the effect of Lycoat® is dominant, the same effect can be
observed here also.
More biorelevant information on the mucoadhesive capacity of the
various Soluplus® films was obtained from the oral cavity model, where
the drug retention from the film formulations was tested on a mucosal
surface under constant rinsing, simulating salivation (Madsen et al.,
2013). In our setup, mucus-producing cells, grown for 3 weeks, were
used as the mucosal surface and PBS pH 7.4 used as simulated saliva.
The flow rate of 1.4mL/min was taken from literature (Dawes, 1996),
and resembled an average of stimulated saliva flow in humans. Fig. 9
indicated that the combination film Soluplus® with HPMC as the mu-
coadhesive polymer (F2), showed the highest retention of the drug to
the mucosal surface, especially for longer times. Films F1 and F3
showed similar profiles, and even though the variation was large be-
tween parallels for film formulation F1, both these formulations were
washed off more rapidly than the Soluplus®-HPMC film (F2). Free drug,
dissolved in PBS, showed no retention on the mucosal surface in the
setup, and > 92% of the API was found rinsed off the mucosa 10min
after application (data not shown). The behaviour of the various films
in the oral cavity model supports the suggested structural character-
istics of the Soluplus® containing films; to avoid rinsing off the mucosa
by salivation, Soluplus® micelles need to be contained in a hydrogel
scaffold of a mucoadhesive polymer. To obtain buccal absorption of
drug the prolonged contact time on the mucosa is an important para-
meter. Increased retention time on the buccal mucosa was achieved for
the mixed HPMC film. HPMC was found to be more successful as a
mucoadhesive scaffold, which might be related to the higher mucin
interaction of this polymer as compared to Lycoat®, but also a con-
tribution of the overall better wetting properties of HPMC recognised in
the lower contact angle (Fig. 5) and higher hygroscopicity (Table 4)
discussed above. As comparison, Roque et al. showed drug retention
between 10–27% after 60min in a similar oral cavity retention model,
with buccal formulations based mainly on HPMC (Roque et al., 2018).
Comparing this to approximately 70% drug retention after 120min
exhibited by the Soluplus®-HPMC films that were tested here, the ad-
vantage is evident. Importantly, the mucoadhesive capacity of the for-
mulations was ranked in the same order by the simple mucin
Table 6
Film dissolution expressed in% dissolved furosemide in solution and micelle size (z-average) and polydispersity index (PDI) (mean± SD, n=3).
Film
formulation





PDI Z-average (nm) Dissolved
furosemide (%)
PDI Z-average (nm) Dissolved
furosemide (%)
PDI Z-average (nm)
5 8.94 ± 8.01 0.045 ± 0.019 65.36 ± 0.36 0.32 n.a. 0.102 ± 0.017 61.29 ± 0.22 9.49 ± 0.48 0.075 ± 0.02 63.02 ± 0.56
7 10.46 ± 7.43 0.036 ± 0.017 64.87 ± 0.19 1.62 n.a. 0.136 ± 0.010 62.40 ± 1.07 10.97 ± 2.77 0.033 ± 0.01 64.88 ± 0.57
10 31.22 ± 31.43 0.036 ± 0.009 62.98 ± 0.09 5.01 ± 4.45 0.075 ± 0.018 62.19 ± 0.26 55.30 ± 25.88 0.044 ± 0.023 62.44 ± 0.58
15 48.82 ± 19.42 0.023 ± 0.019 63.01 ± 0.31 16.26 ± 12.51 0.015 ± 0.008 62.14 ± 0.47 63.49 ± 20.38 0.031 ± 0.014 62.93 ± 0.56
30 102.40 ± 6.50 0.026 ± 0.008 62.57 ± 0.09 24.50 ± 7.21 0.022 ± 0.014 61.93 ± 0.54 78.42 ± 13.13 0.02 ± 0.005 63.02 ± 0.12
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interaction test and the retention to the mucosal surface in the oral
cavity model.
3.6. Buccal transepithelial permeability of film-associated furosemide
Transepithelial permeability of the different Soluplus®-based film
formulations (F1-3) was assessed in a TR146 buccal cell culture model
used to mimic the buccal epithelia (Nielsen and Rassing, 2000).
Transepithelial electrical resistance (TEER) was measured before and
during the incubation with the formulations. The TEER values were
around 270 Ω/cm2 and did not decrease significantly during the mea-
surement period or directly after (supplementary material).
The permeability of furosemide from the three Soluplus®-based
formulations (F1-F3) was similar and no statistical differences were
determined in the apparent permeability coefficients (Papp) or in the
flux (Jflux) between the tested formulations (Table 7). The slight dif-
ference in% cumulative permeability of furosemide at earlier time
points was due to the variations in film formulations F1-F3, (Fig. 10). It
was following the same order as in the retention model, where film
containing HPMC showed lower cumulative permeability in% than a
film containing Soluplus® as single polymer, and a higher retention to
the mucin surface in the retention model. This is likely due to the hy-
drogel scaffold structure of the film being retained for longer, as dis-
cussed earlier, which leads to furosemide releasing more slowly from
Fig. 7. Interactions with mucin and the film formulations, results for F4-F6 are magnified in the insert for clarity (mean±SD, n=10) (unspecific adhesion: no mucin
interaction, general adhesion: with mucin interaction).
Fig. 8. Picture illustrating the over-plasticised effect of wetting a Soluplus®
single polymer film.
Fig. 9. Comparison of furosemide retention on the mucosal surface in films (F1-F3) presented in% (mean± SD, n=3).
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the film matrix. At later time points (60min) the difference is no longer
significant, and all film formulations have similar% cumulative per-
meability. The permeability of free furosemide dissolved in HBSS was
considerately higher and faster than from the formulations. The higher
flux obtained for the free drug was expected as the concentration of the
drug was higher (> 2x higher than for the formulations), which creates
a higher concentration gradient for passive diffusion across the mem-
brane following Fick's first law of diffusion. The lower Papp values of the
film formulations F1-F3, are likely caused by the slower release of
furosemide from Soluplus®micelles (Alopaeus et al., 2019), before drug
is in free solute form and transepithelial permeation can happen. Fur-
thermore, it has been shown that solubilising lipophilic drugs may re-
sult in lowering permeability, where increasing apparent solubility will
result in decreased membrane permeability (Beig et al., 2013;
Dahan et al., 2016). The Papp values obtained for free drug across the
buccal multilayer reflect those values found in literature for perme-
ability across Caco-2 monolayers (Granero et al., 2010; Jung et al.,
2006; Pade and Stavchansky, 1997), but were found to be somewhat
higher in the buccal cells. This might be explained with that furosemide
permeates across cell epithelia through both the paracellular as well as
the transcellular route, governed mostly by the state of ionisation (i.e.
pH of the surrounding liquid) (Pade and Stavchansky, 1997). The
physiological pH of HBSS indicates a high degree of ionisation and in
Caco-2 cells this has been shown to result in a roughly 50:50% dis-
tribution of permeation through paracellular and transcellular routes.
When the permeation was pushed to favour the transcellular pathway
the Papp value increased as well (Pade and Stavchansky, 1997). The
TR146 buccal cells represent stratified epithelia and lack tight junc-
tions; therefore for lipophilic compounds, transepithelial permeation
(i.e. the transcellular path) is usually more favourable compared to
paracellular passive diffusion (Smart, 2005). Furosemide was chosen as
a model drug demonstrating poor solubility and poor permeability (BCS
class IV) (Granero et al., 2010). It is a lipophilic small molecular drug
with a pKa of 3.8 and a logP of approximately 2, and will permeate
through the cell epithelia through passive diffusion when given the
opportunity. Drugs are known to permeate along the route that
provides the least hindrance of passage. This might explain why the
permeability constant is slightly higher in buccal cells as compared to
intestinal cell models. The fact that the drug from film formulations did
not permeate as fast as the free drug in solutions is not necessarily a
disadvantage, as this analysis did not account for the mucoadhesive
properties of the formulations and to a lesser degree for disintegration
kinetics. For buccal permeation, residence time is an important factor,
and the amount of permeated drug will therefore be a sum of per-
meation kinetics and mucoadhesion capacity (Shojaei, 1998).
3.7. Overall discussion
Our working hypothesis was that a rapid disintegration of Soluplus®
was desirable in order to release the micelles containing solubilised
drug, thereby providing the drug in a form that produces a con-
centration gradient over the buccal epithelium ensuring passive diffu-
sion over the barrier. At the same time, increased bioadhesion is ne-
cessary for the micelles to remain in close proximity to the epithelium
for a prolonged period of time to increase the total amount of drug that
permeates. Based on the results obtained in this study there is one
formulation that stands out as the best choice, namely F2, the
Soluplus®-HPMC combination formulation. The results from DVS and
contact angle measurements indicated that these combination films are
hygroscopic and would easily interact and attract moisture. The disin-
tegration test (petri dish method) showed that the disintegration of F2
was complete after 4.5–5min (Table 5), whereas without the hydrogel
scaffold the Soluplus® film disintegrated more rapidly. The erosion test
showed that the mass of F2 was still intact after 6 min (Table 5), and the
oral cavity model suggested that the same formulation could remain on
the mucosa for more than an hour under the simulated saliva flow
employed (Fig. 9). Considered together these findings suggests that the
mechanical stress as well as amount of accessible liquid will strongly
influence the removal of the film from the mucosa. Nevertheless, the
results showed that the hydrogel scaffold, contributed by the added
HPMC, provide support as well as mucoadhesive properties. The dis-
solution test indicated that around 25% of the drug load would be re-
leased after 30min (Table 7) and the permeability studies showed that
available furosemide would permeate the buccal epithelium at a con-
stant rate already from the first time point after 15 min (Fig. 10).
Sufficient retention time to increase the permeability of the drug is
difficult to estimate without doing in vivo studies. However, based on
the various characteristics of the formulations in this study, it might be
realistic to estimate retention on the buccal mucosa as somewhere be-
tween 10min and 30min, maximally 1 h. Naturally, the erosion and
dissolution of the buccal formulation will be greatly influenced by
picking of the tongue, drinking, stimulated salivation and so on.
Therefore, the contribution of the swallowed drug fraction to the ab-
sorbed dose may be regarded as an advantage.
Table 7
The calculated flux (Jflux) and apparent permeability constants (Papp) of fur-
osemide from the three tested films (F1-F3) and free drug dissolved in HBSS
(mean±SD, n=3).
Film formulation Jflux (10−4 µm/cm2•s− 1) Papp (10−6 cm/s)
F1 Soluplus 5.6 ± 0.1 0.9 ± 0.01
F2 Soluplus-HPMC 5.6 ± 0.8 0.9 ± 0.13
F3 Soluplus-Lycoat 7.0 ± 1.8 1.0 ± 0.27
Free drug 31 ± 1.6* 2.1 ± 0.10*
⁎ Significantly different from the other tested formulations (p=<0.05).
Fig. 10. The cumulative permeability of furosemide in three different film formulations (F1-F3) and free drug, represented in% permeated across the cell monolayer.
Values represent mean±SD, n=3.
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The concept as such is not restricted to the model drug used in these
studies, but could work equally well for other poorly soluble, small
molecular APIs, and also small biological drugs, such as peptides should
be investigated. The concept may also be used for local treatment in the
oral cavity.
Even though, in vivo studies would be required to obtain the final
proof of the hypothesis that the mucin-retentive scaffold provide the
mucoadhesion that result in increased permeability, the current results
strongly suggest that the F2 formulation is promising in this respect.
The logical next step in the product development is to test these systems
in an animal model.
4. Conclusions
The novel buccal delivery system investigated in this study com-
bines the solubilisation and nanocarrier capabilities of Soluplus®, with
the mucoadhesive properties of an additive polymer, that allow pro-
longed contact with the mucosal surface, in a dry and user-friendly oral
film. Mixed films of Soluplus® with HPMC or Lycoat®, disintegrated into
a hydrogel structure where the micelles were maintained in a suppor-
tive scaffold of the added hydrophilic polymer. The combination film
with Lycoat® dispersed upon agitation and did not show increased
mucoadhesive properties, when tested towards a mucosal surface under
constant simulated salivation. The combination film with HPMC, on the
other hand, showed higher retention even after longer rinsing times. All
Soluplus® containing films showed similar permeability in buccal
TR146 epithelial cells and the permeability was superior to reported
permeability in intestinal cell models. The combination film Soluplus®-
HPMC showed the most promise as a novel buccal formulation, espe-
cially in terms of mucoadhesion properties and resistance to erosion,
which resulted in increased drug retention on the mucosal surface.
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